Orthopediatrics (KIDS) EBITDA (2016 - 2026)

Orthopediatrics' EBITDA history runs 11 years deep, the most recent figure standing at -$8.3 million for Q1 2026.

• In Q1 2026, EBITDA rose 24.1% year-over-year to -$8.3 million; the TTM figure through Mar 2026 stood at -$36.6 million (down 0.89% YoY), while the FY2025 annual figure was -$39.2 million, down 12.08% from the prior year.
• EBITDA was -$8.3 million for Q1 2026 at Orthopediatrics, down from -$8.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$3.7 million in Q2 2022 to a low of -$14.1 million in Q4 2024.
• Historically, EBITDA has averaged -$7.9 million across 5 years, with a median of -$8.2 million in 2025.
• The sharpest annual moves came in 2022 and 2025: EBITDA tumbled 91.03% in 2022, then jumped 41.86% in 2025.
• A 5-year view of EBITDA shows it stood at -$8.3 million in 2022, then advanced by 2.92% to -$8.1 million in 2023, then plunged by 74.25% to -$14.1 million in 2024, then surged by 41.86% to -$8.2 million in 2025, then slipped by 1.99% to -$8.3 million in 2026.
• The last three EBITDA figures came in at -$8.3 million (Q1 2026), -$8.2 million (Q4 2025), and -$9.4 million (Q3 2025), per Business Quant data.